Editas Medicine, Inc. EDIT
Set alert
2.67 USD -0.26 -8.87%
At close · Oct 30
2.70 +0.03 +1.12%
After hours · Oct 30, 5:35 PM ET
2.60 Day range 2.92
1.66 52-week range 3.75
- YTD
- +30.24%
- 1 year
- -11.30%
- Open
- 2.89
- Prev close
- 2.93
- Mkt cap
- 410.06M
- Vol
- 2.91M
- Avg vol
- 2.66M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.60
- High
- 2.92
- Forward P/E
- -0.53
- Beta
- 2.01
- Short ratio
- 6.70
- Inst. own
- 70.94%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.60
- 200-d avg
- 4.55
- 1y target
- 3.67
5Y chart
Events in this range
- Aug 2, 2023Earnings: -0.56; estimate -0.76; surprise 26.32%
- Nov 3, 2023Earnings: -0.55; estimate -0.64; surprise 14.06%
- Feb 28, 2024Earnings: -0.23; estimate -0.52; surprise 55.77%
- May 8, 2024Earnings: -0.76; estimate -0.63; surprise -20.63%
- Aug 7, 2024Earnings: -0.82; estimate -0.69; surprise -18.84%
- Nov 4, 2024Earnings: -0.75; estimate -0.76; surprise 1.32%
- Dec 13, 2024Rating: Baird · Outperform → Outperform
- Dec 13, 2024Downgrade: Chardan Capital · Buy → Neutral
- Dec 13, 2024Rating: Barclays · Equal-Weight → Equal-Weight
- Dec 13, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 16, 2024Downgrade: JP Morgan · Neutral → Underweight
- Dec 16, 2024Rating: Evercore ISI Group · Outperform → Outperform
Signals (94)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| MACD: Sell Signal | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Nov 18, 2024 | 1 year ago |
| RSI: Oversold | Nov 18, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 11, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 31, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 10, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 23, 2023 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| RSI: Oversold | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 103.19M
- Enterprise value
- -118.46M
- Trailing P/E
- 0.00
- Forward P/E
- -0.53
- PEG ratio
- 0.00
- Price / sales
- 1.67
- Price / book
- 0.59
- EPS (TTM)
- -2.54
- Beta
- 2.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 61.76M
- Revenue growth
- -98.90%
- Free cash flow
- -113.80M
- Total cash
- 265.09M
- Total debt
- 38.49M
- Return on equity
- -78.56%
- Shares outstanding
- 82.55M
- Short % of float
- 24.64%
- 50-day average
- 2.60
- 200-day average
- 4.55
Analyst view
Consensus: hold
Hold
Price target (mean) 3.67 +37.3% upside
Now 2.67
- Target (low)
- 1.00
- Target (mean)
- 3.67
- Target (high)
- 8.00
Ratings (0m) 18 4 buy · 12 hold · 2 sell
- Strong buy0
- Buy4
- Hold12
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -0.3561.
Financials — quick view
EDIT Revenue — quarterly 11.89M
EDIT Net income — quarterly -18.23M
EDIT EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.76 | -0.75 | +0.01 | +1.32% |
| Aug 7, 2024 | Jun 1, 2024 | -0.69 | -0.82 | -0.13 | -18.84% |
| May 8, 2024 | Mar 1, 2024 | -0.63 | -0.76 | -0.13 | -20.63% |
| Feb 28, 2024 | Dec 1, 2023 | -0.52 | -0.23 | +0.29 | +55.77% |
| Nov 3, 2023 | Sep 1, 2023 | -0.64 | -0.55 | +0.09 | +14.06% |
| Aug 2, 2023 | Jun 1, 2023 | -0.76 | -0.56 | +0.20 | +26.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Dec 16, 2024 | JP Morgan | down | Neutral | Underweight |
| Dec 13, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 13, 2024 | Barclays | main | Equal-Weight | Equal-Weight |
| Dec 13, 2024 | Chardan Capital | down | Buy | Neutral |
| Dec 13, 2024 | Baird | main | Outperform | Outperform |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- editasmedicine.com
News
- Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average – Here’s Why
- Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
- EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
- Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
- Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
- Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average – Here’s Why
- TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
- This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
- Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Your note
Sign in to keep a note on EDIT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURKLY LINDA | Officer | Sale | Jul 24, 2024 | 73,136 |
| EATON BRUCE E | Chairman of the Board | Sale | Dec 4, 2023 | 74,791 |
| HOPFIELD JESSICA | Director | Purchase | May 12, 2024 | 67,700 |
| LUCERA ERICK J. | Chief Financial Officer | Sale | May 19, 2024 | 116,829 |
| MEI BAISONG | Officer | Sale | Dec 2, 2024 | 133,354 |
| O NEILL GILMORE NEIL | Chief Executive Officer | Sale | Dec 2, 2024 | 312,106 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.72% | 8,024,709 | 10.03M | Sep 29, 2024 |
| Vanguard Group Inc | 8.09% | 6,679,606 | 8.35M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.94% | 4,900,334 | 6.13M | Sep 29, 2024 |
| Millennium Management Llc | 4.06% | 3,350,856 | 4.19M | Sep 29, 2024 |
| State Street Corporation | 2.98% | 2,462,022 | 3.08M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.75% | 2,267,110 | 2.83M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 2,591,876 | 3.24M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.61% | 2,152,572 | 2.69M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.65% | 1,359,023 | 1.70M | Sep 29, 2024 |
| Vanguard Strategic Equity Fund | 1.44% | 1,189,890 | 1.49M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.03% | 850,449 | 1.06M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.95% | 784,487 | 980.61K | Oct 30, 2024 |